- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03720392
Fecal Microbiota Transplantation (FMT) in Recipients After Allogeneic Hematopoietic Cell Transplantation (HCT)
A Phase 2 Study of Fecal Microbiota Transplantation (FMT) in Recipients After Allogeneic Hematopoietic Cell Transplantation (HCT)
Study Overview
Status
Intervention / Treatment
Detailed Description
This research study is a Phase II clinical trial. Phase II clinical trials test the safety and effectiveness of an investigational intervention to learn whether the intervention works in treating a specific disease. "Investigational" means that the intervention is being studied.
The FDA (the U.S. Food and Drug Administration) has not approved FMT for this use.
After HCT, the body's microbiome (the natural existence of various bacteria and organisms) in the intestinal tract may be affected, in that the number and types of good bacteria is reduced (also called a reduction in microbial flora diversity). Studies have shown that the number and types of good bacteria in the gut can impact whether or not a person develop a disease called graft-versus-host disease (GVHD). GVHD occurs when donated bone marrow cells attack the body with an immune response. Researchers believe that more microbial flora diversity in the gut is linked to a lower risk of developing GVHD.
FMT is a process utilizing microbial components which are the good, healthy bacteria that would otherwise naturally occur in the body. Since the participant may have decreased microbial flora diversity after HCT, these microbial components are taken from a 3rd party donor. They are extracted from fecal matter (stool) and put into a capsule which the participant then ingest.
Researchers believe that FMT administration may play a role in restoring higher microbial flora diversity in the gut. Therefore, FMT administration may play a role in decreasing the likelihood of developing GVHD.
In this research study, the investigators are...
- Examining the microbial flora diversity of your gut after FMT administration
- Looking for incidence rate of GVHD and other post-HCT complications
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02214
- Massachusetts General Hospital Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Men or women ≥ 18 and ≤ 80 years old
- Patients designated to undergo myeloablative or intermediate intensity allogeneic peripheral blood or bone marrow hematopoietic cell transplantation. Consent will be obtained prior to admission for HSCT. Patients receiving any donor source of stem cells are eligible. Eligible conditioning regimens are those defined as myeloablative by the ASBMT Consensus Criteria (Bacigalupo 2009) as well as the combination of fludarabine with melphalan (100-140 mg/mg2)
- Any GVHD prophylaxis regimen is allowed.
- ECOG performance status ≤ 2 (Karnofsky ≥ 60%, see Appendix A)
Patients with adequate physical function as measured by
- Cardiac: Left ventricular ejection fraction at rest must be ≥ 40%, or shortening fraction >25%
- Hepatic:
- Bilirubin ≤ 2.5 mg/dL, except for patients with Gilbert's syndrome or hemolysis
- ALT, AST, and Alkaline Phosphatase < 5 x ULN
- Renal: Serum creatinine within normal range, or if serum creatinine is outside normal range, then renal function (measured or estimated creatinine clearance or GFR) ≥ 40mL/min/1.73m2
- Pulmonary: DLCO (corrected for hemoglobin), FEV1 and FVC ≥ 50% predicted
- Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Women of childbearing potential will have a urine pregnancy test, which must be negative, on Study Day 1, prior to receiving FMT. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study and for 3 months after FMT.
- Ability to understand and the willingness to sign a written informed consent document, including the willingness to accept risk of unrelated donor stool.
- Ability to swallow large capsules.
Exclusion Criteria:
- Prior allogeneic hematopoietic stem cell transplantation. (Patients may have received a prior autologous hematopoietic stem cell transplant.)
- Participants who are receiving any other investigational agents.
- Uncontrolled intercurrent illness including, but not limited to, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
- Patients with active or uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy.
- Planned use of prophylactic donor lymphocyte infusion (DLI) therapy.
- Delayed gastric emptying syndrome or large hiatal hernia
- Known chronic aspiration
- Participants with a history of significant allergy to foods not excluded from the donor diet (excluded foods are tree nuts, peanuts, shellfish, eggs)
- Pregnant and breast-feeding women are ineligible because they are not eligible for hematopoietic stem cell transplantation.
- HIV-positive participants are ineligible.
- Participants who are unable to swallow pills.
- Participants with end-stage liver disease (cirrhosis)
- Participants with acute, active gastrointestinal infection (e.g., typhlitis, diverticulitis, appendicitis)
- Participants with inflammatory bowel disease (e.g., ulcerative colitis, Crohn's)
- Prior total colectomy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: FMT Capsules
|
FMT is a process utilizing microbial components which are the good, healthy bacteria that would otherwise naturally occur in the body.
|
Placebo Comparator: Placebo Capsules
|
a harmless pill, medicine, or procedure prescribed more for the psychological benefit to the patient than for any physiological effect.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The Proportion of Patients Who Achieve Gut Microbiome Diversity at One Month Following the Final Post-HCT FMT
Time Frame: 1 Month
|
Gut microbiome diversity will be assessed using urinary 3-indoxyl sulfate (3-IS) levels, with 35 umol/mmol creatinine as the cutoff (≥ 35: diverse; < 35: not diverse).
|
1 Month
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Acute Graft-Versus-Host-Disease (GvHD)
Time Frame: 6 months
|
The cumulative incidence of overall grades II-IV and grades III-IV acute GVHD will be assessed through six months after last dose of FMT or placebo.
Acute GVHD will be assessed using the Mount Sinai Acute GVHD International Consortium (MAGIC) criteria.
|
6 months
|
Number of Participants With Non-relapse-mortality
Time Frame: 6 Months and 12 months
|
Non-relapse mortality (NRM) is defined as the time from first dose of FMT or placebo to death without relapse or progression or underlying disease.
|
6 Months and 12 months
|
Number of Participants With Infection at 100 Days
Time Frame: 100 Days
|
100 Days
|
|
Number of Participants With Progression Free Survival at 12 Months Post-treatment
Time Frame: 12 Months
|
Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.
Progression-Free Survival (PFS) is defined as the time from first dose of FMT or placebo to the earlier of underlying disease progression or death due to any cause.
PFS was assessed at 12 months for all participants.
|
12 Months
|
Overall Survival
Time Frame: 12 Months
|
Overall survival is measured as the amount of time from the first dose of Fecal Microbiota Transplantation (FMT) or placebo, that participants in this study are still alive.
Overall survival is reported as number of participants alive at 12 months.
|
12 Months
|
Graft Versus Host Disease(GVHD)/ Relapse Free Survival (GRFS)
Time Frame: 12 Months
|
GVHD-Free/Relapse-Free Survival (GRFS) is measured as the amount of time from the first dose of Fecal Microbiota Transplantation (FMT) or placebo, that participants in this study are not diagnosed with GVHD, disease progression, or relapse.
GRFS is reported as number of patients without GVHD, disease progression, or relapse at 12 months.
|
12 Months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Zachariah DeFilipp, MD, Massachusetts General Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- 18-293
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Allogeneic Hematopoietic Cell Transplantation (HCT)
-
Duke UniversityNot yet recruitingHematopoietic Cell Transplantation (HCT)
-
Duke UniversityActive, not recruitingHematopoietic Steam Cell Transplantation (HCT)United States
-
Pluristem Ltd.CompletedIncomplete HCT (Hematopoietic Cell Transplantation)United States, Israel
-
University Hospital, GenevaRecruitingAllogeneic Hematopoietic Stem Cell Transplantation | Hematopoietic Stem Cell Transplantation | Autologous Hematopoietic Stem Cell TransplantationSwitzerland
-
Children's Hospital Medical Center, CincinnatiTerminatedAllogeneic Hematopoietic Cell TransplantationUnited States
-
Children's Hospital Medical Center, CincinnatiRecruitingAllogeneic Hematopoietic Cell TransplantationUnited States
-
Case Comprehensive Cancer CenterRecruitingAllogeneic Hematopoietic Cell TransplantationUnited States
-
Children's Hospital Medical Center, CincinnatiCompleted
-
Sidney Kimmel Cancer Center at Thomas Jefferson...National Cancer Institute (NCI)TerminatedALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATIONUnited States
-
Universitaire Ziekenhuizen KU LeuvenUnknownHematopoietic Stem Cell Transplantation | Hematopoietic Stem Cell Transplantation, Allogeneic
Clinical Trials on FMT
-
University of North Carolina, Chapel HillThe Broad Foundation; Crohn's and Colitis Foundation; OpenBiomeTerminated
-
University GhentUniversity Hospital, Ghent; Research Foundation Flanders; the Flanders Institute... and other collaboratorsCompleted
-
Fondazione Policlinico Universitario Agostino Gemelli...Recruiting
-
The University of Hong KongUnknownDevelopmental Coordination DisorderHong Kong
-
Fondazione Policlinico Universitario Agostino Gemelli...Not yet recruitingEnterobacteriaceae Infections | Multi-antibiotic ResistanceItaly
-
Universitaire Ziekenhuizen KU LeuvenFund for Scientific Research, Flanders, BelgiumUnknown
-
Fondazione Policlinico Universitario Agostino Gemelli...RecruitingUlcerative Colitis | Clostridium DifficileItaly
-
Fondazione Policlinico Universitario Agostino Gemelli...RecruitingEnterobacteriaceae Infections | Multi-antibiotic ResistanceItaly
-
Aleris-Hamlet Hospitaler KøbenhavnUniversity of Aarhus; Hvidovre University HospitalCompletedIrritable Bowel SyndromeDenmark
-
McMaster UniversitySt. Joseph's Healthcare Hamilton; Hamilton Health Sciences Corporation; Queen... and other collaboratorsCompletedClostridium Difficile InfectionCanada